Swedish study refutes link between treatment for high blood pressure and cancer (p 539)

August 16, 2001

Please note that if you are outside North America, the embargo for press material is 0001 hours UK Time Friday 17 August 2001.

A Swedish study published in this week's issue of THE LANCET refutes the theory that treatment for high blood pressure (hypertension) could be linked to an increased risk of cancer.

Debate over a possible association between the use of antihypertensive drugs (eg. diuretics, ß-blockers, angiotensin-converting enzyme [ACE] inhibitors), and an increased risk of cancer (notably breast cancer and kidney cancer) has prevailed over the past 25 years; however no plausible explanations have been identified. Lars Hjalmar Lindholm and colleagues from Umea University, Sweden, studied a Swedish population of elderly people (who had previously taken part in a prospective cardiovascular study) to identify whether antihypertensive treatments resulted in an increased incidence of cancer.

Around 6600 patients with hypertension (average age 76 years, average follow-up time 5.3 years) were randomly assigned to one of three treatment strategies: conventional drugs (diuretics or ß-blockers), calcium antagonists, or ACE inhibitors. The patients were matched to the Swedish Cancer Registry and the frequency of cancer-related deaths were compared with expected values based on age, sex, and calendar-year-specific reference frequencies for the general Swedish population. Cancer frequencies were also compared between the three treatment groups.

607 (9%) patients had a history of malignant disease at the start of the study. During follow-up, there were 625 new cases of cancer in 590 patients. The frequency of cancer did not differ significantly compared with the general Swedish population, and there was no difference in cancer incidence between groups with different treatment strategies.

Lars Hjalmar Lindholm comments: "Our study does not lend support to the hypothesis that any of the three treatment strategies promote cancer, nor to the hypothesis that any of these strategies protect against cancer. Thus, a drug regimen that effectively lowers blood pressure is more important than the risk of cancer."
-end-
Contact: Professor Lars Hjalmar Lindholm, Department of Public Health and Clinical Medicine, Umea University, SE 901 85 Umea, Sweden; T) 46-90-785326; F) 46-90-776883; E) LarsH.Lindholm@fammed.umu.se

Lancet

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.